Discover our Purpose

Gerosynth Labs is a life sciences company dedicated to developing real solutions for modern medicine’s unmet needs. Guided by our core values of honesty, integrity, and transparency, we’re working to transform how the world treats cancer and to shape the future of regenerative medicine by delivering breakthrough innovations to those who need them most.

Equine nutritional supplement

Mytulin EQ by Gerosynth Labs is a supplement for immune health, cellular health, and performance recovery in horses. The product supports musculoskeletal health, gastrointestinal balance, and mitochondrial rejuvenation.

Gerosynth Labs Announces Investigational New Animal Drug (INAD) Acceptances Spanning Equine, Feline, and Canine Oncology

Gerosynth Labs, Inc., a private biotechnology company pioneering novel oncology and cellular-health therapeutics, today announced that the U.S. Food and Drug Administration Center for Veterinary Medicine (CVM) has accepted multiple Investigational New Animal Drug (INAD) files for the company’s lead oncology candidates across equine, feline, and canine categories.

Gerosynth Labs Announces Launch of Mytulin EQ, an Advanced Equine Nutritional Supplement

Gerosynth Labs, Inc., a private biotechnology company specializing in pharmaceutical preparations for oncology and regenerative health, and parent company of Mytosynth Nutraceuticals, LLC, today announced the launch of Mytulin EQ, a next-generation equine nutritional supplement designed to support immune health, cellular vitality, and performance recovery.

Developed through proprietary phytochemical research, Mytulin EQ promotes musculoskeletal strength, gastrointestinal balance, and mitochondrial rejuvenation—key factors in optimizing equine health and longevity.

Get in Touch